Home  /  Resource Library  /  Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma

Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma

Article discusses results of a clinical trial combining Brentuximab Vedotin with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or doxorubicin, vinblastine, and dacarbazine (AVD ) for advanced stage Hodgkin.